Description
Bionic Ears Market size was estimated at USD 22.52 billion in 2021, growing at a CAGR of 8.2% during the forecast period 2022-2028. A bionic ear is an electronic device that is designed by electrically stimulating nerves in the inner ear of deaf patients to produce hearing sensation. It consists of a receiver-stimulator implanted below patient’s skin behind the ear and sound processor. These processors stimulate the inner ear’s nerves which send signals to the brain where these signals are interpreted as sound. The bionic ear is beneficial for people who are suffering from severe, profound or total loss of hearing. Standard hearing aid devices work by amplifying sound, but it is only useful for people with the partial loss of hearing not for people who are deaf or have profoundly impaired hearing. Loss of hearing is associated with the damage or other abnormalities in the tiny sensor hair cells present inside the cochlea or inner ear. To overcome such conditions bionic ears are used. Bionic ears market is expected to show considerable growth over the forecast period. As per WHO, more than 360 Mn people are affected by loss of hearing disability globally. Loss of hearing is one of the leading global disorder. According to the Royal National Institute for Deaf People (RNID), the prevalence rate of hearing disorder is growing with the age, which is affecting about 70% of people over 70 and 42% people over 50. Geriatric people are highly susceptible to loss of hearing that can affect their social life. Due to this factor, bionic ear market is expected show significant growth. Untreated loss of hearing among newborn can affect their entire life. As it can lead to impairment in speaking and affect their psychological abilities. But due to technological advancement and development of bionic ears, it is now possible to help these children. Also due to increasing awareness and better diagnostic facilities to detect the problem number of cases are being registered among newborn children. Research institutes such as Bionics Institute are aiming at improving the performance of bionic ears and function of hearing nerves.
Key Developments:
In July 2017, Cochlear Limited introduced Cochlear Nucleus 7 Sound Processor into the U.S. market and it was by U.S. FDA
In August 2015, Advanced Bionics (AB), a subsidiary of Switzerland-based Sonova received the U.S.FDA approval for Naída CI Q90 and Q30 sound processors